Dogwood Therapeutics, Inc (NASDAQ:DWTX) Stock Short Interest Report for October

Dogwood Therapeutics, Inc (NASDAQ:DWTX – Get Free Report) saw a large growth in short interest in the month of October. As of October 30th, there was short interest totaling 111,693 shares, a growth of 79.0% from the October 15th total of 62,406 shares. Based on an average daily volume of 67,836 shares, the days-to-cover ratio is currently 1.6 days. Approximately 0.3% of the company’s shares are sold short.

Dogwood Therapeutics Stock Performance

Shares of DWTX opened at $1.08 on Wednesday. The company has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.88. Dogwood Therapeutics has a twelve month low of $0.90 and a twelve month high of $7.04.

Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.02. The company had revenue of $0.10 million during the quarter, compared to analysts’ expectations of $0.10 million. Equities analysts expect that Dogwood Therapeutics will post -0.78 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Thursday, October 22nd. HC Wainwright restated a “buy” rating on shares of Dogwood Therapeutics in a report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and an average target price of $12.00.

View Our Latest Stock Report on Dogwood Therapeutics

About Dogwood Therapeutics

(Get Free Report)

Dogwood Therapeutics is a clinical-stage biopharmaceutical company developing investigational treatments for chronic pain and fatigue-related disorders. Its work includes therapies intended to address conditions with limited treatment options. The company’s pipeline includes Halneuron, a tetrodotoxin-based candidate being studied for chronic pain, and IMC-1, an investigational combination of famciclovir and celecoxib studied for fibromyalgia. Dogwood also has other development programs, including IMC-2.

Further Reading

Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.